Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with st-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention pharmacodynamic study

Circulation: Cardiovascular Interventions

Volumn 7, Issue 2, 2014, Pages 233-239

  Alexopoulos, Dimitrios ^a   Makris, George ^a   Xanthopoulou, Ioanna ^a   Patsilinakos, Sotirios ^b   Deftereos, Spyridon ^b   Gkizas, Vassilios ^a   Perperis, Angelos ^a   Karanikas, Stavros ^b   Angelidis, Christos ^b   Tsigkas, Grigorios ^a   Koutsogiannis, Nikolaos ^a   Hahalis, George ^a   Davlouros, Periklis ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

Author keywords

Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; HIRULOG; PRASUGREL; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HUMAN; LOADING DRUG DOSE; MALE; MIDDLE AGED; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PLATELET REACTIVITY; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STATISTICAL ANALYSIS; THROMBOCYTE FUNCTION ANALYZER; AGED; BLOOD; BLOOD CLOTTING; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; ELECTROCARDIOGRAPHY; MYOCARDIAL INFARCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; TIME; TREATMENT OUTCOME;

ADULT; AGED; BLOOD COAGULATION; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84900448436     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.113.001118     Document Type: Article

References (26)

1. Jakubowski JA, Payne CD, Brandt JT, Weerakkody GJ, Farid NA, Small DS, Naganuma H, Li GY, Winters KJ. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol. 2006;47:377-384.
2. Asai F, Jakubowski JA, Naganuma H, Brandt JT, Matsushima N, Hirota T, Freestone S, Winters KJ. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Platelets. 2006;17:209-217.
3. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923-2932.
4. Zhu B, Effron MB, Kulkarni MP, Li YG, Jakubowski JA, Miller DL, Baker BA, Luo J, Small DS, Winters KJ. The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data. J Cardiovasc Pharmacol. 2011;57:317-324.
5. Michelson AD, Frelinger AL III, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD; TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009;30:1753-1763.
6. Alexopoulos D. P2Y12 inhibitors adjunctive to primary PCI therapy in STEMI: fighting against the activated platelets. Int J Cardiol. 2013;163:249-255.
7. Campo G, Valgimigli M, Frangione A, Tebaldi M, Ferrari R. Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. J Thromb Haemost. 2008;6:1824-1826.
8. Biscaglia S, Tebaldi M, Vranckx P, Campo G, Valgimigli M. Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention. J Thromb Haemost. 2013;11:192-194.
9. Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R; FABOLUS PRO Investigators. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with STsegment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv. 2012;5:268-277.
10. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012;5:797-804.
11. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, Antoniucci D. Comparison of Prasugrel and Ticagrelor loading doses in STEMI patients: The Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI Study. J Am Coll Cardiol. 2013;61:1601-1606.
12. Alexopoulos D, Xanthopoulou I, Davlouros P, Plakomyti TE, Panagiotou A, Mavronasiou E, Hahalis G. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am Heart J. 2011;162:733-739.
13. Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, Dangas G. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol. 2011;58:1945-1954.
14. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011;124:1132-1137.
15. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736-2747.
16. Alexopoulos D, Theodoropoulos KC, Stavrou EF, Xanthopoulou I, Kassimis G, Tsigkas G, Damelou A, Davlouros P, Hahalis G, Athanassiadou A. Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction. Cardiovasc Drugs Ther. 2012;26:393-400.
17. Heestermans AA, van Werkum JW, Taubert D, Seesing TH, von Beckerath N, Hackeng CM, Schomig E, Verheugt FW, ten Berg JM. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res. 2008;122:776-781.
18. Alexopoulos D, Gkizas V, Patsilinakos S, Xanthopoulou I, Angelidis C, Anthopoulos P, Makris G, Perperis A, Karanikas S, Koutsogiannis N, Davlouros P, Deftereos S, Chiladakis J, Hahalis G. Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI. J Am Coll Cardiol. 2013;62:940-941.
19. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010;50:126-42
20. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376:1312-1319.
21. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P; ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999-1010.
22. Campo G, Saia F, Guastaroba P, Marchesini J, Varani E, Manari A, Ottani F, Tondi S, De Palma R, Marzocchi A. Prognostic impact of hospital readmissions after primary percutaneous coronary intervention. Arch Intern Med. 2011;171:1948-1949.
23. Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther. 2009;7:1195-1201.
24. Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, Shaburishvili T, Huber K, Prats J, Liu T, Harrington RA, Becker RC. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012;34:44-55.
25. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsky P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303-1313.
26. Montalescot G, Lassen JF, Hamm CW, Lapostolle F, Silvain J, ten Berg JM, Cantor WJ, Goodman SG, Licour M, Tsatsaris A, van't Hof AW. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double- blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. Am Heart J. 2013;165:515-522.